News & Updates

EMPEROR-Preserved: The first successful trial to improve outcomes in HFpEF

18 Nov 2021

Heart failure with preserved ejection fraction (HFpEF) represents a significant unmet medical need. The EMPEROR-Preserved trial aimed to assess the impact of empagliflozin on cardiovascular outcomes in patients with HFpEF. On 27 August 2021, during the hotline session of the 2021 ESC Virtual Congress, the main results of the EMPEROR-Preserved trial were presented by Professor Stefan Anker, principal investigator of the study, and heart failure specialist at Charité Berlin, Germany.

EMPEROR-Preserved: The first successful trial to improve outcomes in HFpEF

18 Nov 2021

NOACs in nonvalvular atrial fibrillation with multimorbidity: Where does apixaban stand?

02 Nov 2021

Atrial fibrillation (AF) is the most common cardiac arrhythmia encountered in clinical practice, affecting millions of people globally. Stroke is one of its devastating complications, with the risk steeply increasing with advancing age. Additionally, AF is associated with more than a tripling of the risk of systemic embolic (SE) events. [J Am Heart Assoc 2020;9:e016724]

NOACs in nonvalvular atrial fibrillation with multimorbidity: Where does apixaban stand?

02 Nov 2021

Kids hard-hit by Delta; which ART performs best?

24 Oct 2021 by

That COVID-19 mostly spared children might be changing. The Delta variant has taken a severe, unthinkable toll on kids – at least in Arkansas, US, reports an expert at IDWeek 2021.

Kids hard-hit by Delta; which ART performs best?

24 Oct 2021

Rapid antigen test: Don’t let perfect be the enemy of good

23 Oct 2021 by

While rapid antigen test is less sensitive than conventional nucleic acid amplification test (NAAT) such as RT-PCR* in detecting SARS-CoV-2 virus, “a test does not have to be perfect to be clinically useful,” said Professor Angela Caliendo during a session in IDWeek 2021 — echoing the maxim that perfect should not be the enemy of good in the pandemic era.